


PHARMACEUTICAL 2023

ABBOTT LABORATORIES Rank 50 of 446









RealRate

PHARMACEUTICAL 2023

ABBOTT LABORATORIES Rank 50 of 446



The relative strengths and weaknesses of ABBOTT LABORATORIES are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABBOTT LABORATORIES compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 101% points. The greatest weakness of ABBOTT LABORATORIES is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 241%, being 198% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	25,224,000
Cost of Goods Sold	19,142,000
Intangible Assets	33,253,000
Liabilities, Current	15,489,000
Liabilities, Non-Current	0
Other Assets	6,799,000
Other Compr. Net Income	323,000
Other Expenses	3,944,000
Other Liabilities	0
Other Net Income	502,000
Other Revenues	43,653,000
Property and Equipment	9,162,000
Research and Development	2,888,000
Selling, General and Administrative Expense	11,248,000

Output Variable	Value in 1000 USD
Assets	74,438,000
Liabilities	15,489,000
Expenses	37,222,000
Revenues	43,653,000
Stockholders Equity	58,949,000
Net Income	6,933,000
Comprehensive Net Income	7,094,500
Economic Capital Ratio	241%

